Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has launched its Fenofibrate Tablets, 48 mg and 145 mg strengths in the United States. Lupin had earlier received final approval for the same from the US Food and Drug Administration (FDA).
Lupin's Fenofibrate tablets are the AB rated generic equivalent of Abbott's TRICOR* tablets and are indicated for Primary Hypercholesterolemia or Mixed Dyslipidemia and Severe Hypertriglyceridemia. Abbott's TRICOR* Tablets, 48 mg and 145 mg had sales of U5D 1.26 billion as per IMS Health, June, 2012,
Commenting on the approval, Vinita Gupta, CEO, Lupin Pharmaceuticals Inc. & Group President, Lupin Limited said, "We are very happy to bring this product to market in the United States. Patients can be assured that they are receiving the same high quality product they have been accustomed to at a more affordable price".
India Infoline News Service / 14:51, Aug 19, 2014
Q1 revenues declined 0.9% qoq vs our estimate for a 1.8% qoq on the back of weakness in global operations whose revenues declined 14.9% qoq and 5.1% yoy.